Cook social media site to educate on ED

Share this article:
In an effort to educate physicians and consumers about a complex and painful form of erectile dysfunction know as Peyronie's disease, device manufacturer Cook Medical recently launched an unbranded physician education focused website found online at

The social networking microsite was designed to provide the most current information on Peyronie's, offering professionals and their patients public forums for discussing the disease.

“We are starting to think about how the future readers of medical news will gather their information,” said SVP and global strategic business unit leader for Cook Urology, Jerry French. “When I talk to urologists now, these people are getting their information online. One of the hallmarks for Cook has always been education, especially on the physician side,” French said. “Peyronie's is an issue that not a lot of people know about. We figured this would be a good opportunity for us to test the water on social media.”

Cook Medical is the maker of Surgisis Biodesign, a technology used for the replacement and repair of damaged human tissue in surgery. Surgisis Biodesign is used in various procedures, including Peyronie's repair. Surgisis Biodesign is derived from the small intestine of pigs and communicates with the body by signaling surrounding tissue to grow.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in News

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.